Pseudomonal airway colonisation: Risk factor for bronchiolitis obliterans syndrome after lung transplantation?

European Respiratory Journal

Volumn 31, Issue 5, 2008, Pages 1037-1045

  Vos, R ^a   Vanaudenaerde, B M ^a   Geudens, N ^a   Dupont, L J ^a,b   Van Raemdonck, D E ^a,b   Verleden, G M ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Airway colonisation; Bronchiolitis obliterans syndrome; Lung transplantation; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; COLISTIN; CYCLOSPORIN; TACROLIMUS;

ADULT; AIRWAY DYNAMICS; ARTICLE; BACTERIAL COLONIZATION; BRONCHIOLITIS OBLITERANS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG FIBROSIS; LUNG INFECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS; RISK FACTOR; SPUTUM CULTURE; SURVIVAL RATE; CYSTIC FIBROSIS; DISEASE FREE SURVIVAL; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; SPUTUM;

ADULT; BRONCHIOLITIS OBLITERANS; BRONCHOALVEOLAR LAVAGE FLUID; CYSTIC FIBROSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PSEUDOMONAS; RETROSPECTIVE STUDIES; RISK FACTORS; SPUTUM;

EID: 47049131058     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00128607     Document Type: Article

References (55)

1. Yabuuchi E, Kosako Y, Oyaizu H, et al. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol 1992; 36: 1251-1275.
2. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001; 14: 336-363.
3. Qvarfordt I, Riise GC, Andersson BA, Larsson S. Lower airway bacterial colonization in asymptomatic smokers and smokers with chronic bronchitis and recurrent exacerbations. Respir Med 2000; 94: 881-887.
4. Cabello H, Torres A, Celis R, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997; 10: 1137-1144.
5. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003; 2: 29-34.
6. Proesmans M, Balinska-Miskiewicz W, Dupont L, et al. Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J 2006; 27: 937-943.
7. Nunley DR, Grgurich W, Iacono AT, et al. Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients. Chest 1998; 113: 1235-1243.
8. de Pablo A, López S, Ussetti P, et al. [Lung transplant therapy for suppurative diseases.] Arch Bronconeumol 2005; 41: 255-259.
9. Bonvillain RW, Valentine VG, Lombard G, LaPlace S, Dhillon G, Wang G. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. J Heart Lung Transplant 2007; 26: 890-897.
10. Schaedel C, de Monestrol, I, Hjelte L, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002; 33: 483-491.
11. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006; 73: 27-33.
12. Jones AM, Dodd ME, Govan JR, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004; 59: 948-951.
13. Greene CM, Carroll TP, Smith SG, et al. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol 2005; 174: 1638-1646.
14. Tseng J, Do J, Widdicombe JH, Machen TE. Innate immune responses of human tracheal epithelium to Pseudomonas aeruginosa flagellin, TNF-α, and IL-1β. Am J Physiol Cell Physiol 2006; 290: C678-C690.
15. Delgado MA, Poschet JF, Deretic V. Nonclassical pathway of Pseudomonas aeruginosa DNA-induced interleukin-8 secretion in cystic fibrosis airway epithelial cells. Infect Immun 2006; 74: 2975-2984.
16. Tosi MF, van Heeckeren A, Ferkol TW, Askew D, Harding CV, Kaplan JM. Effect of Pseudomonas-induced chronic lung inflammation on specific cytotoxic T-cell responses to adenoviral vectors in mice. Gene Ther 2004; 11: 1427-1433.
17. Vos R, VanaudenaerdeBM, Dupont LJ, Van Raemdonck DE, Verleden GM. Transient airway colonization is associated with airway inflammation after lung transplantation. Am J Transplant 2007; 7: 1278-1287.
18. Firoved AM, Ornatowski W, Deretic V. Microarray analysis reveals induction of lipoprotein genes in mucoid Pseudomonas aeruginosa: implications for inflammation in cystic fibrosis. Infect Immun 2004; 72: 5012-5018.
19. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report-2006. J Heart Lung Transplant 2006; 25: 880-892.
20. De Soyza A, Archer L, Wardle J, et al. Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis. J Heart Lung Transplant 2003; 22: 764-769.
21. Dobbin C, Maley M, Harkness J, et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect 2004; 56: 277-282.
22. Botha P, Archer L, Anderson RL, et al. Colonization of lung transplant recipients with Pseudomonas aeruginosa and the development of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2006; 25: Suppl. 1, 82.
23. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15: 1-15.
24. Standardization of Spirometry - 1987 Update. Statement of the American Thoracic Society. Am Rev Respir Dis 1987; 136: 1285-1298.
25. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
26. Hachem RR, Chakinala MM, Yusen RD, et al. The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am J Respir Crit Care Med 2004; 169: 468-472.
27. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002; 21: 271-281.
28. Cook DJ, Fitzgerald JM, Guyatt GH, Walter S. Evaluation of the protected brush catheter and bronchoalveolar lavage in the diagnosis of nosocomial pneumonia. J Intensive Care Med 1991; 6: 196-205.
29. Mueller EW, Wood GC, Kelley MS, Boucher BA, Fabian TC, Croce MA. The predictive value of preliminary bacterial colony counts from bronchoalveolar lavage in critically ill trauma patients. Am Surg 2003; 69: 749-755.
30. Chan CC, Abi-Saleh WJ, Arroliga AC, et al. Diagnostic yield and therapeutic impact of flexible bronchoscopy in lung transplant recipients. J Heart Lung Transplant 1996; 15: 196-205.
31. Rust M, Albera C, Carratu L, et al. The clinical use of BAL in patients with pulmonary infections. Eur Respir J 1990; 3: 954-959.
32. Belda J, Cavalcanti M, Ferrer M, et al. Bronchial colonization and postoperative respiratory infections in patients undergoing lung cancer surgery. Chest 2005; 128: 1571-1579.
33. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015-1022.
34. Van Delden C, Iglewski BH. Cell-to-cell signaling and Pseudomonas aeruginosa infections. Emerg Infect Dis 1998; 4: 551-560.
35. Wilson R, Dowling RB. Lung infections. 3. Pseudomonas aeruginosa and other related species. Thorax 1998; 53: 213-219.
36. Chambers CE, Visser MB, Schwab U, Sokol PA. Identification of N-acylhomoserine lactones in mucopurulent respiratory secretions from cystic fibrosis patients. FEMS Microbiol Lett 2005; 244: 297-304.
37. Wolfgang MC, Jyot J, Goodman AL, Ramphal R, Lory S. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. Proc Natl Acad Sci USA 2004; 101: 6664-6668.
38. Erickson DL, Endersby R, Kirkham A, et al. Pseudomonas aeruginosa quorum-sensing systems may control virulence factor expression in the lungs of patients with cystic fibrosis. Infect Immun 2002; 70: 1783-1790.
39. Middleton B, Rodgers HC, Cámara M, Knox AJ, Williams P, Hardman A. Direct detection of N-acylhomoserine lactones in cystic fibrosis sputum. FEMS Microbiol Lett 2002; 207: 1-7.
40. Ward C, Camara M, Forrest I, et al. Preliminary findings of quorum signal molecules in clinically stable lung allograft recipients. Thorax 2003; 58: 444-446.
41. Gillis RJ, White KG, Choi KH, Wagner VE, Schweizer HP, Iglewski BH. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2005; 49: 3858-3867.
42. Hooi DS, Bycroft BW, Chhabra SR, Williams P, Pritchard DI. Differential immune modulatory activity of Pseudomonas aeruginosa quorum-sensing signal molecules. Infect Immun 2004; 72: 6463-6470.
43. Zimmermann S, Wagner C, Müller W, et al. Induction of neutrophil chemotaxis by the quorum-sensing molecule N-(3-oxododecanoyl)- L-homoserine lactone. Infect Immun 2006; 74: 5687-5692.
44. Lewenza S, Visser MB, Sokol PA. Interspecies communication between Burkholderia cepacia and Pseudomonas aeruginosa. Can J Microbiol 2002; 48: 707-716.
45. Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164: 1628-1632.
46. Vanaudenaerde BM, Wuyts WA, Dupont LJ, Van Raemdonck DE, Demedts MM, Verleden GM. Interleukin-17 stimulates release of interleukin-8 by human airway smoothmuscle cells in vitro: a potential role for interleukin-17 and airway smooth muscle cells in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22: 1280-1283.
47. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174: 566-570.
48. Reynaud-Gaubert M, Marin V, Thirion X, et al. Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration. J Heart Lung Transplant 2002; 21: 721-730.
49. Holzmann D, Speich R, Kaufmann T, et al. Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10-year experience. Transplantation 2004; 77: 134-136.
50. Vanaudenaerde BM, Wuyts WA, Geudens N, et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 2007; 7: 76-82.
51. Rasmussen TB, Givskov M. Quorum sensing inhibitors: a bargain of effects. Microbiology 2006; 152: 895-904.
52. Tateda K, Comte R, Pechere JC, Köhler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001; 45: 1930-1933.
53. Nalca Y, Jänsch L, Bredenbruch F, Geffers R, Buer J, Häussler S. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother 2006; 50: 1680-1688.
54. Hurst JR, Wilkinson TM, Perera WR, Donaldson GC, Wedzicha JA. Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest 2005; 127: 1219-1226.
55. Hadjiliadis D, Chaparro C, Gutierrez C, et al. Impact of lung transplant operation on bronchiolitis obliterans syndrome in patients with chronic obstructive pulmonary disease. Am J Transplant 2006; 6: 183-189.